XTX Topco Ltd Takes $321,000 Position in Immatics (NASDAQ:IMTX)

XTX Topco Ltd purchased a new position in shares of Immatics (NASDAQ:IMTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 27,587 shares of the company’s stock, valued at approximately $321,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Trexquant Investment LP grew its holdings in Immatics by 4.2% during the 4th quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock worth $471,000 after acquiring an additional 1,801 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Immatics by 14.3% during the second quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock worth $232,000 after purchasing an additional 2,500 shares during the last quarter. Nan Fung Group Holdings Ltd acquired a new position in Immatics in the first quarter worth about $165,000. ADAR1 Capital Management LLC bought a new stake in Immatics in the fourth quarter valued at about $232,000. Finally, TD Asset Management Inc increased its holdings in Immatics by 14.9% in the fourth quarter. TD Asset Management Inc now owns 227,118 shares of the company’s stock valued at $2,392,000 after buying an additional 29,400 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th.

Immatics Price Performance

IMTX stock opened at $11.73 on Friday. The firm has a fifty day moving average price of $11.76 and a two-hundred day moving average price of $11.56. Immatics has a 1-year low of $7.15 and a 1-year high of $13.77. The firm has a market cap of $993.06 million, a price-to-earnings ratio of -11.07 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The firm had revenue of $20.19 million for the quarter, compared to analyst estimates of $12.36 million. As a group, analysts expect that Immatics will post -0.99 EPS for the current fiscal year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.